Summary
- Profile Type
- Technology offer
- POD Reference
- TOES20250429019
- Term of Validity
- 29 April 2025 - 29 April 2026
- Company's Country
- Spain
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A research group from CIBER, Universidad de Malaga (UMA) and Servicio Andaluz de Salud (SAS) has identified new blood cells biomarkers related to Type-1 Diabetes that could improve the early diagnosis of this disorder. A company willing to implement and commercialize the technology through a license agreement or a technical agreement is sought.
- Full Description
-
The Andalusian research team belongs to the University of Malaga and works in the field of diabetes.
Some of the activities carried out by the research group are focused on the field of endocrinology, diabetes and obesity. The present invention provides new biomarkers for an early diagnosis or screening for Type-1 Diabetes, consisting in a minimal invasive method, safe for the subject and simple to put in practice.
Backgroud: Commonly, the clinical diagnosis of diabetes takes place when a vast number of beta-cells have been lost, causing a great problem in the blood glucose regulation. Nowadays there are no biomarkers previous to the clinical appearance of the disease, that’s why there is a strong need of early diagnosis for early stages of this disorder, in order to establish a new therapeutic approach to prevent or delay the Type-1 Diabetes debut.
Thus, there is a need in the present technical field to develop new biomarkers for an early diagnosis or screening for Type-1 Diabetes, consisting in a minimal invasive method, safe for the subject and simple to put in practice. - Advantages and Innovations
-
The main innovate aspect of the method is that it is based on the expression of certain genes related with the cannabinoid system in mononuclear peripheric blood cells.
This new method presents an alternative to the commonly used diagnosis methods for Type-1 Diabetes, where the disorder is in a more advanced state.
The method uses a kit for a quick and early diagnosis. - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- A Wordwide (PCT countries) protection application.
Partner Sought
- Expected Role of a Partner
-
Type: The team is looking for industrial partners interested in implementing and commercializing the technology worldwide. Companies that want to enter into a licensing agreement or alternatively technical agreement, in order to explore the new possibilities in the health sector are sought.
Role of partner: companies that wish to obtain patent rights as a licensee to implement and commercialize the technology at international level. - Type and Size of Partner
- SME <=10
- Big company
- SME 11-49
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06002004 - Protein Engineering
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001007 - Other diagnostic
- 04006 - Cellular and Molecular Biology
- Sector Groups Involved
- Health
- Targeted countries
- All countries